Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Uro-Pain Dual Action (methenamine / sodium salicylate)
- urokinase
Interactions between your drugs
urokinase sodium salicylate
Applies to: urokinase, Uro-Pain Dual Action (methenamine / sodium salicylate)
MONITOR CLOSELY: Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.
MANAGEMENT: Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment. Local guidelines and prescribing information for individual thrombolytic drugs should be consulted for further recommendations.
References (8)
- (2001) "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc
- (2001) "Product Information. Abbokinase (urokinase)." Abbott Pharmaceutical
- (2001) "Product Information. Activase (alteplase)." Genentech
- (2001) "Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals
- (2001) "Product Information. Retavase (reteplase)." Boehringer Mannheim
- (2001) "Product Information. TNKase (tenecteplase)." Genentech
- Harder S, Klinkhardt U (2000) "Thrombolytics: drug interactions of clinical significance." Drug Saf, 23, p. 391-9
- Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians (2001) "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest, 119(1 Suppl), 1S-2S
Drug and food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
Detrol
Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
VESIcare
Vesicare is used to treat symptoms of overactive bladder such as incontinence and frequent ...
Ditropan
Ditropan XL (oxybutynin extended release) is used to treat the symptoms of overactive bladder ...
Fesoterodine
Fesoterodine is used for overactive bladder, urinary frequency, urinary incontinence
Trospium
Trospium is used for interstitial cystitis, overactive bladder, urinary frequency, urinary incontinence
Tolterodine
Tolterodine is used for overactive bladder, urinary frequency, urinary incontinence
Mirabegron
Mirabegron is used for neurogenic detrusor overactivity, overactive bladder, urinary frequency ...
Solifenacin
Solifenacin (Vesicare) is used to treat overactive bladder symptoms such as frequent or urgent ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.